Musculoskeletal Oncology: Advances in Cytogenetics and Molecular Genetics and their Clinical Implications

References

• Enzinger F M, Weiss S W. Soft tissue tumorsThird edition. CV Mosby, St Louis, Mo 1995; 1–16
   Google Scholar
• Schajowicz F. Tumors and tumorlike lesions of boneSecond edition. Springer-Verlag, Berlin 1994; 1–27
   Google Scholar
• Gustafson P. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Acta Orthop Scand 1994; 65: 1–31
   PubMedGoogle Scholar
• Fletcher C D M. Introduction. Pathobiology of soft tissue tumors, C D M Fletcher, P H Mc-Kee. Churchill Livingstone, Edinburgh 1990; 1–7
   Google Scholar
• Fletcher C D. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992; 16: 213–28
   PubMed Web of Science ®Google Scholar
• Weh H J, Hossfeld D K. Systemic therapy of disseminated soft tissue sarcomas. Recent results in cancer research, M Bamberg, W Hoffmann, D K Hossfeld. Springer-Verlag, Berlin 1995; 147–59
   Google Scholar
• Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12: 1137–49
   PubMed Web of Science ®Google Scholar
• Benjamin R S. Adjuvant chemotherapy of soft tissue sarcomas in North America. Recent results in cancer research, M Bamberg, W Hoffman, D K Hossfeld. Springer-Verlag, Berlin 1995; 139–45
   Google Scholar
• Sandberg A A, Turc-Carel C. The cytogenetics of solid tumors. Relation to diagnosis, classification and pathology. Cancer 1987; 59: 387–95
   PubMed Web of Science ®Google Scholar
• Nowell P C. The clonal evolution of tumor cell populations. Science 1976; 194: 23–8
   PubMed Web of Science ®Google Scholar
• Boveri T. Zur Frage der Enststehung maligner Tumoren. Gustav Fisher Verlag. 1914
   Google Scholar
• Culver K W, Vickers T M, Lamsam J L, Walling H W, Seregina T. Gene therapy for solid tumors. Br Med Bull 1995; 51: 192–204
   PubMedGoogle Scholar
• Boveri T. The origin of malignant tumours. The Williams and Wilkins Co., Baltimore 1929; 26–7
   Google Scholar
• Aisenberg A C. New genetics of Burkitt's lymphoma and other non-Hodgkin's lymphoma. Am J Med 1984; 77: 1083–90
   PubMed Web of Science ®Google Scholar
• Knudson A G. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820–38
   PubMed Web of Science ®Google Scholar
• Friend S H, Bernards R, Rogelj S. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643–6
   PubMed Web of Science ®Google Scholar
• Eng C, Li F P, Abramson D H, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 1993; 85: 1121–8
   PubMed Web of Science ®Google Scholar
• Abramson D H, Ellsworth R M, Kitchin F D, Tung G. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced?. Opthalmology 1984; 91: 1351–5
   PubMed Web of Science ®Google Scholar
• Schimke R N, Lowman J T, Cowan A B. Retinoblastoma, and osteogenic sarcoma in siblings. Cancer 1974; 34: 2077–9
   PubMedGoogle Scholar
• Lee W-H, Shew J Y, Hong F, et al. The retinoblastoma susceptibility gene product is a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329: 642–5
   PubMed Web of Science ®Google Scholar
• Chellappan S P, Hiebert S, Mudryi M, Horowitz J M, Nevins J R. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053–61
   PubMed Web of Science ®Google Scholar
• Robbins P D, Horowitz J M, Mulligan R C. Negative regulation of human c-fos expression by the retinoblastoma gene product. Nature 1990; 346: 668–71
   PubMed Web of Science ®Google Scholar
• Santhanam U, Ray A, Sehgal P B. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1991; 88: 7605–9
   PubMed Web of Science ®Google Scholar
• Hansen M F, Xu H J, Zhao J, Hu S X, Raymond A K, Benedict W F. Expression patterns of the retinoblastoma susceptibility gene in conventional and variant histology osteosarcoma. Frontiers of osteosarcoma research. Interdisciplinary survey of clinical and research advances, J F Novak, J H McMaster. Hogrefe and Huber, Seattle 1993; 347–57
   Google Scholar
• Araki N, Atsumasa U, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft tissue tumors. Clin Orthop 1991; 270: 271–7
   PubMedGoogle Scholar
• Lane D P, Crawford L V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261–3
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler K W. p53 function and dysfunction. Cell 1992; 70: 523–6
   PubMed Web of Science ®Google Scholar
• Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009–22
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Karp J E, Broder S. Molecular foundations of cancer: New targets for intervention. Nat Med 1995; 1: 309–20
   PubMed Web of Science ®Google Scholar
• Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52: 6194–9
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794–9
   PubMed Web of Science ®Google Scholar
• Miller C, Aslo A, Tsay C, et al. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 1990; 50: 7950–4
   PubMed Web of Science ®Google Scholar
• Birch J M. Li-Fraumeni syndrome. Eur J Cancer 1994; 30A: 1935–41
   PubMedGoogle Scholar
• Li F P, Fraumeni J F. Prospective study of a family cancer syndrome. JAMA 1982; 247: 2692–4
   PubMed Web of Science ®Google Scholar
• Toguchida J. Clinical relevance of tumor suppressor gene mutations in osteosarcoma. Frontiers of osteosarcoma research. Interdisciplinary survey of clinical research, J F Novak, J H McMaster. Hogrefe and Huber, Seattle 1993; 337–57
   Google Scholar
• Wadayama B, Toguchida J, Yamaguchi T, Sasaki M S, Kotoura Y, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 1993; 68: 1134–9
   PubMed Web of Science ®Google Scholar
• Andreassen Å, Øyjord T, Hovig E, et al. p53 abnormalities in different subtypes of human sarcomas. Cancer Res 1993; 53: 468–71
   PubMed Web of Science ®Google Scholar
• Leach F S, Tokino T, Meltzer P, et al. P53 mutation and MDM2 amplification in human soft tissue sarcoma. Cancer Res 1993; 53: 2231–4
   PubMed Web of Science ®Google Scholar
• Rowley J D. The Philadelphia chromosome translocation–A paradigm for understanding leukemia. Cancer 1990; 65: 2178–84
   PubMed Web of Science ®Google Scholar
• Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases and remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32: 229–38
   PubMed Web of Science ®Google Scholar
• Squire J, Zielenska M, Thorner P, et al. Variant translocations of chromosome 22 in Ewing's sarcoma. Genes Chromosom Cancer 1993; 8: 190–4
   PubMed Web of Science ®Google Scholar
• Sorensen P H B, Lessnick S L, Lopez-Terrada D, Liu X F, Triche T J, Denny C T. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994; 6: 146–51
   PubMed Web of Science ®Google Scholar
• Jeon I-S, Davis J N, Braun B S, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995; 10: 1229–34
   PubMed Web of Science ®Google Scholar
• Mugneret F, Lizard S, Aurias A, Ture-Carel C. Chromosomes in Ewing's sarcoma. II Nonrandom additional changes, trisomy 8 and der(16)t(1;16). Cancer Genet Cytogenet 1988; 32: 239–45
   PubMedGoogle Scholar
• Ladanyi L, Heinemann F S, Huvos A G, Rao P H, Chen Q G, Jhanwar S C. Neural differentiation in small round cell tumors of bone and soft tissue with the translocation t(11;22)(q24;q12): an immunohistochemical study of 11 cases. Hum Pathol 1990; 21: 1245–51
   PubMedGoogle Scholar
• Kees U R, Rudduck C, Ford J, et al. Two malignant peripheral neuroepithelial tumor cell lines established from consecutive samples of one patient. Genes Chromosom Cancer 1992; 4: 195–204
   PubMedGoogle Scholar
• Zucman J, Delattre O, Desmaze C, et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosom Cancer 1992; 5: 271–7
   PubMed Web of Science ®Google Scholar
• Whang-Peng J, Freter C E, Knutsen T, Nanfro J J, Gazdar A. Translocation t(11;22) in esthesioneuroblastoma. Cancer Genet Cytogenet 1987; 29: 155–7
   PubMedGoogle Scholar
• Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162–5
   PubMed Web of Science ®Google Scholar
• May W A, Gishizky M L, Lessnick S L, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI-1 for transformation. Proc Natl Acad Sci USA 1993; 90: 5752–6
   PubMed Web of Science ®Google Scholar
• Eneroth M, Mandahl N, Heim S, et al. Localisation of the chromosomal breakpoints of the t(12;16) in liposarcoma to subbands 12q13.3 and 16p11.2. Cancer Genet Cytogenet 1990; 48: 101–7
   PubMedGoogle Scholar
• Turc-Carel C, Limon J, Dal-Cin P, Rao U, Karakousis C, Sandberg A A. Cytogenetic studies of adipose tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcoma. Cancer Genet Cytogenet 1986; 23: 291–9
   PubMed Web of Science ®Google Scholar
• Sreekantaiah C, Karakousis C P, Leong S P L, Sandberg A A. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. Cancer 1992; 69: 2484–95
   PubMed Web of Science ®Google Scholar
• Pedeutour F, Suijkerbuijk R F, Van Gaal J, et al. Chromosome 12 origin in rings and giant markers in well-differentiated liposarcoma. Cancer Genet Cytogenet 1993; 66: 133–4
   PubMedGoogle Scholar
• Pedeutour F, Suijkerbuijk R F, Forus A, et al. Complex composition and coamplification of SAS and MDM2 in ring and giant rod marker chromosomes in well-differentiated liposarcoma. Genes Chromosom Cancer 1994; 10: 85–94
   PubMed Web of Science ®Google Scholar
• Rabbitts T H, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993; 4: 175–80
   PubMed Web of Science ®Google Scholar
• Crozat A, Åman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993; 363: 640–4
   PubMed Web of Science ®Google Scholar
• Ron D, Habener J F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant negative inhibitor of gene transcription. Genes Dev 1992; 6: 439–45
   PubMed Web of Science ®Google Scholar
• Limon J, Mrozek K, Mandahl N, et al. Cytogenetics of synovial sarcoma: presentation of ten new cases and review of the literature. Genes Chromosom Cancer 1991; 3: 338–45
   PubMed Web of Science ®Google Scholar
• Enzinger F M, Weiss S W. Synovial sarcoma. Soft tissue tumorsThird edition. CV Mosby, St Louis, MO 1995; 757–86
   Google Scholar
• Mandahl N, Limon J, Mertens F, et al. Nonrandom secondary chromosome aberrations in synovial sarcomas with t(X;18). Int J Oncol 1995; 7: 495–9
   PubMedGoogle Scholar
• Clark J, Rocques P J, Crew A J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 1994; 7: 502–8
   PubMed Web of Science ®Google Scholar
• de Leeuw B, Balemans M, Weghuis D O, et al. Molecular cloning of the synovial sarcoma-specific translocation (X;18) (p11.2;q11.2) breakpoint. Hum Mol Genet 1994; 3: 745–9
   PubMed Web of Science ®Google Scholar
• Smith S, Reeves B R, Wong L, Fisher C. A consistent chromosomal translocation in synovial sarcomas. Cancer Genet Cytogenet 1987; 26: 179–80
   PubMed Web of Science ®Google Scholar
• Enzinger F M, Weiss S W. Rhabdomyosarcoma. Soft tissue tumorsThird edition. CV Mosby, St Louis, MO 1995; 539–78
   Google Scholar
• Douglas E C, Shapiro D N, Valentine M, et al. Alveolar rhabdomyosarcoma with the t(2;13) cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 1993; 21: 83–7
   PubMedGoogle Scholar
• Whang-Peng J, Knutsen T, Horowitz M E, Triche T J. Cytogenetic studies in subgroup of rhabdomyosarcoma. Genes Chromosom Cancer 1992; 5: 299–310
   PubMed Web of Science ®Google Scholar
• Biegel J A, Meek R S, Parmiter A H, Conrad K, Emanuel B S. Chromosome translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma. Genes Chromosom Cancer 1991; 3: 483–4
   PubMed Web of Science ®Google Scholar
• Douglas E C, Rowe S T, Valentine M, et al. Variant translocations of chromosome 13 in alveolar rhabdomyosarcoma. Genes Chromosom Cancer 1991; 3: 480–2
   PubMedGoogle Scholar
• Fletcher J A, Kozakewich H P, Pavelka K, et al. Consistent cytogenetic aberrations in hepatoblastoma: a common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies?. Genes Chromosom Cancer 1991; 3: 37–43
   PubMed Web of Science ®Google Scholar
• Koufos A, Grundy P, Morgan K, et al. Familial Wiedemann-Beckwith syndrome and a second Wilms/apos tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44: 711–9
   PubMed Web of Science ®Google Scholar
• Galili N, Davis R J, Fredericks W J, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 5: 230–5
   PubMed Web of Science ®Google Scholar
• Barr F G, Galili N, Holick J, Biegel J A, Rovera G, Emanuel B S. Rearrangement of the PAX3 paired box gene in the paediatric solid tumor alveolar rhabdomyosarcoma. Nat Genet 1993; 3: 113–7
   PubMed Web of Science ®Google Scholar
• Burri M, Tromvoukis Y, Bopp D, Frigerio G, Noll M. Conservation of the paired domain in metazoans and its structure in three isolated human genes. EMBO J 1989; 8: 1183–90
   PubMedGoogle Scholar
• Goulding M D, Chalepakis G, Deutsch U, Erselius J R, Gruss P. Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. EMBO J 1991; 10: 1135–47
   PubMed Web of Science ®Google Scholar
• Sasaki H, Hogan B L M. Differential expression of multiple fork head related genes during gastrulation and axial pattern formation in the mouse embryo. Development 1993; 118: 47–59
   PubMed Web of Science ®Google Scholar
• Hacker U, Grossniklaus U, Gehring W J, Jackle H. Developmentally regulated Drosophila gene family encoding the forkhead domain. Proc Nat Acad Sci USA 1992; 89: 8754–8
   PubMed Web of Science ®Google Scholar
• Li J, Vogt P K. The retroviral oncogene qin belongs to the transcription factor family that includes the homeotic gene fork head. Proc Natl Acad Sci USA 1993; 90: 4490–4
   PubMed Web of Science ®Google Scholar
• Clevidence D E, Overdier D G, Tao W, et al. Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding domain family. Proc Natl Acad Sci USA 1993; 90: 3948–52
   PubMed Web of Science ®Google Scholar
• Davis R J, D'Cruz C M, Lovell M A, Biegel J A, Barr F G. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869–72
   PubMed Web of Science ®Google Scholar
• Davis R J, Bennicelli J L, Macina R A, Nycum L M, Biegel J A, Barr F G. Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. Hum Mol Genet 1995; 4: 2355–62
   PubMed Web of Science ®Google Scholar
• Fletcher J A. Translocation (12;22)(q13–14;q12) is a non-random aberration in soft tissue clear-cell sarcoma. Genes Chromosom Cancer 1992; 5: 184
   PubMedGoogle Scholar
• Peulve P, Michot C, Vannier J-P, Tron P, Hemet J. Clear cell sarcoma with t(12;22)(q13–14;q12). Genes Chromosom Cancer 1991; 3: 400–2
   PubMed Web of Science ®Google Scholar
• Kindblom L-G, Lodding P, Angervall A. Clear-cell sarcoma of tendons and aponeurones. An immunohistochemical and electron microscopic analysis indicating neural crest origin. Virchows Arch Pathol Anat 1983; 409: 109–28
   Google Scholar
• Stenman G, Andersson H, Mandahl N, Meis-Kindblom J M, Kindblom L-G. Translocation t(9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995; 62: 398–402
   PubMedGoogle Scholar
• Örndal C, Carlén B, Åkerman M, et al. Chromosomal abnormality t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry. Cytopathology 1991; 2: 261–70
   PubMedGoogle Scholar
• Labelle Y, Zucman J, Stenman G, et al. Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum Mol Genet 1995; 4: 2219–26
   PubMed Web of Science ®Google Scholar
• Gill S, McManus A P, Crew A J, et al. Fusion of the EWS gene to a segment from 9q22–31 in a human myxoid chondrosarcoma. Genes Chromosom Cancer 1995; 12: 307–10
   PubMedGoogle Scholar
• Mandahl N, Heim S, Willén H, et al. Characteristic karyotypic anomaties identify subtypes of malignant fibrous histiocytoma. Genes Chromosom Cancer 1989; 1: 9–14
   PubMed Web of Science ®Google Scholar
• Rydholm A, Mandahl N, Heim S, Kreicbergs A, Willén H, Mitelman F. Malignant fibrous histiocytomas with a 19p + marker chromosome have increased relapse rate. Genes Chromosom Cancer 1990; 2: 296–9
   PubMedGoogle Scholar
• Nilbert M, Rydholm A, Willén H, Mitelman F, Mandahl N. MDM2 gene amplification correlates with ring chromosomes in soft tissue tumors. Genes Chromosom Cancer 1994; 9: 261–5
   PubMed Web of Science ®Google Scholar
• Mitelman F. Catalog of chromosome aberrations in cancerFifth ed. Wiley-Liss, New York 1994
   Google Scholar
• Choong P F M, Mandahl N, Mertens F, et al. 19p + marker chromosome correlates with relapse in malignant fibrous histiocytoma. Genes Chromosom Cancer 1996; 16: 88–93
   PubMed Web of Science ®Google Scholar
• Hoogerwerf W A, Hawkins A L, Perlman E J, Griffin C A. Chromosome analysis of nine osteosarcomas. Genes Chromosom Cancer 1994; 9: 88–92
   PubMed Web of Science ®Google Scholar
• Biegel J A, Womer R B, Emanuel B S. Complex karyotypes in a series of pediatric osteosarcomas. Cancer Genet Cytogenet 1989; 38: 89–100
   PubMed Web of Science ®Google Scholar
• Mertens F, Mandahl N, Örndal C, et al. Cytogenetic findings in 33 osteosarcomas. Int J Cancer 1993; 55: 44–50
   PubMed Web of Science ®Google Scholar
• Örndal C, Mandahl N, Rydholm A, Willén H, Brosjö O, Mitelman F. Chromosome aberrations and cytogenetic intratumor heterogeneity in chondrosarcomas. J Cancer Res Clin Oncol 1993; 120: 51–6
   PubMedGoogle Scholar
• Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F. Chromosomal rearrangements in chondromatous tumors. Cancer 1990; 65: 242–8
   PubMedGoogle Scholar
• Nilbert M, Rydholm A, Mitelman F, Meltzer P S, Mandahl N. Characterization of the 12q13–15 amplicon in soft tissue tumors. Cancer Genet Cytogenet 1995; 83: 32–6
   PubMedGoogle Scholar
• Ladanyi M, Cha C, Lewis R, Jhanwar S C, Huvos A G, Healey J H. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53: 16–8
   PubMed Web of Science ®Google Scholar
• Oliner J D, Kinzler K W, Meltzer P S, George D L, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80–3
   PubMed Web of Science ®Google Scholar
• Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wildtype p53 activity. EMBO J 1993; 12: 461–8
   PubMed Web of Science ®Google Scholar
• Pedeutour F, Simon M-P, Minoletti F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res 1995; 55: 2400–3
   PubMed Web of Science ®Google Scholar
• Kampe C E, Rosen G, Eilber G, et al. Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localised disease. Cancer 1993; 72: 2161–9
   PubMed Web of Science ®Google Scholar
• Bridge J A, Neff J R, Mouron B J. Giant cell tumor of bone: chromosomal analysis of 48 specimens and review of the literature. Cancer Genet Cytogenet 1992; 58: 2–13
   PubMedGoogle Scholar
• Örndal C, Mandahl N, Rydholm A, et al. Supernumerary ring chromosomes in five bone and soft tissue tumors of low or borderline malignancy. Cancer Genet Cytogenet 1992; 60: 170–5
   PubMedGoogle Scholar
• Fletcher C D M, Åkerman M, Dal Cin P, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) collaborative study group. Am J Pathol 1995; 148: 623–30
   Google Scholar
• Enneking W F. A system of staging musculoskeletal neoplasms. Clin Orthop 1986; 204: 9–24
   Google Scholar
• Alvegård T A, Berg N O, Baldetorp B, et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol 1990; 8: 538–47
   PubMed Web of Science ®Google Scholar
• Choong P F M, Åkerman M, Willén H, et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific?. APMIS 1995; 103: 797–805
   PubMedGoogle Scholar
• Choong P F M, Åkerman M, Willén H, et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomsa. Proliferation—a marker of metastasis?. APMIS 1994; 102: 915–24
   PubMedGoogle Scholar
• Choong P F M, Gustafson P, Willén H, et al. Prognosis following locally recurrent soft-tissue sarcoma. A staging system based on primary and recurrent tumor characteristics. Int. J. Cancer 1995; 60: 33–7
   PubMed Web of Science ®Google Scholar
• Mandahl N, Heim S, Arheden K, Rydholm A, Willén H, Mitelman F. Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet 1988; 79: 203–8
   PubMed Web of Science ®Google Scholar
• Bridge J A, Bhatia P S, Anderson J R, Neff J R. Biologic and clinical significance of cytogenetic and molecular cytogenetic abnormalities in benign and malignant cartilaginous lesions. Cancer Genet Cytogenet 1993; 69: 79–90
   PubMedGoogle Scholar
• Patel S R, Burgess M A, Plager C, Papadopoulos N E, Linke K A, Benjamin R S. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265–9
   PubMed Web of Science ®Google Scholar
• Yandell D W, Campbell T A, Dayton A H, et al. Oncogenic point mutations in the human retinoblastoma gene: their appplication to genetic counseling. N Engl J Med 1989; 321: 1689–95
   PubMed Web of Science ®Google Scholar
• Wunder J S, Czitrom A A, Kandel R, Andrulis I L. Analysis of alterations in retinoblastoma gene and tumor grade in bone and soft tissue sarcomas. J Natl Cancer Inst 1991; 83: 194–200
   PubMed Web of Science ®Google Scholar
• Cance W G, Brennan M F, Dudas M E, Huang C-M, Cordoncardo C. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med 1990; 323: 1457–62
   PubMed Web of Science ®Google Scholar
• Skuse G R, Ludlow J W. Tumor suppressor genes in disease and therapy. Lancet 1995; 345: 902–6
   PubMed Web of Science ®Google Scholar